stockrowAurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- 0.00%
- Free cash flow
- +4.41%
- Total debt
- −30.0%
Quarter to September 2026, against a year earlier
Follow AUPH
Alert me
Aurinia Pharmaceuticals Inc (AUPH) EPS (diluted)
Aurinia Pharmaceuticals Inc's EPS (diluted) for fiscal 2025 was $2.07, up 5,075.0% from $0.04 in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.29. Over the past ten years it has ranged from −$1.40 (fiscal 2021) to $2.07 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 4 consecutive fiscal years. Aurinia Pharmaceuticals Inc ranks 26th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $2.07 | 5,075.00% |
| FY2024 | $0.04 | — |
| FY2023 | −$0.54 | — |
| FY2022 | −$0.76 | — |
| FY2021 | −$1.40 | — |
| FY2020 | −$0.87 | — |
| FY2019 | −$0.95 | — |
| FY2018 | −$0.76 | — |
| FY2017 | −$0.92 | — |
| FY2016 | −$0.66 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.23 | (17.86%) |
| Jun 2026 | $0.28 | 12.00% |
| Mar 2026 | $0.25 | (83.66%) |
| Dec 2025 | $1.53 | 565.22% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc | $2.29 |
| ADMA ADMA Biologics Inc compare | $0.77 |
| VCEL Vericel Corporation compare | $0.65 |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$0.29 |
| IMNM Immunome, Inc. compare | −$2.53 |
| BHVN Biohaven Ltd. compare | −$3.86 |
| CLDX Celldex Therapeutics, Inc. compare | −$4.35 |
| PVLA Palvella Therapeutics, Inc. compare | −$4.83 |
| VERA Vera Therapeutics, Inc. compare | −$5.86 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on AUPH
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement